Skip Navigation LinksHome > September 2013 - Volume 34 - Issue 9 > Estimated background doses of [67Ga]-DTPA-USPIO in normal Ba...
Nuclear Medicine Communications:
doi: 10.1097/MNM.0b013e328362d2fb
Original Articles

Estimated background doses of [67Ga]-DTPA-USPIO in normal Balb/c mice as a potential therapeutic agent for liver and spleen cancers

Shanehsazzadeh, Saeeda,c; Oghabian, Mohammad A.a,c; Lahooti, Afsaneha; Abdollahi, Mohammadf; Abolghasem Haeri, Seyedd; Amanlou, Massoudb; Daha, Fariba J.e; Allen, Barry J.g

Collapse Box


Introduction: The aim of this study was to evaluate the biodistribution of dextran-coated iron oxide nanoparticles labeled with gallium-67 (67Ga) in various organs by intravenous injection in Balb/c mice.

Methods: Ultrasmall superparamagnetic iron oxide (USPIO) was successively labeled with 67Ga-chloride after chelation with freshly prepared cyclic DTPA-dianhydride. The labeling efficiency of USPIOs labeled with 67Ga is above 98%. Sixty-five mice were killed at 13 different time points. The percentage of injected dose per gram of each organ was measured by direct counting for 19 harvested organs of the mice. The medical internal radiation dose formula was applied to extrapolate data from mouse to human and to predict the absorbed radiation dose for various organs in the human body.

Results: The biodistribution of 67Ga-USPIO in Balb/c mice showed that 75% of the injected dose accumulated in the spleen and liver 15 min after injection. These nanoparticles remained in the liver for more than 7 days after injection, whereas their clearance was very fast from other organs. Extrapolating these data to the intravenous injection of 67Ga-USPIO in humans gave an estimated absorbed dose of 36.38 mSv/MBq for the total body, and the highest effective absorbed dose was seen in the liver (32.9 mSv/MBq).

Conclusion: High uptakes of USPIO nanoparticles in the liver and spleen and their fast clearance from other tissues suggest that these nanoparticles labeled with a β-emitter radioisotope could be suitable as treatment agents for spleen and liver malignancies only if the organ tolerance dose is not exceeded.

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.